Metabolic Disturbances Independent of Body Mass in Patients with Schizophrenia Taking Atypical Antipsychotics
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveaaAtypical antipsychotic (AAP) treatment is associated with weight gain and metabolic disturbances such as dyslipidemia and dysglycemia. The metabolic disturbances are usually considered to develop secondary to weight gain. We performed the comparison of metabolic disturbances of three AAP group with different risk of metabolic side effect after adjusting for body mass to investigate whether any metabolic disturbances develop independently from body mass index (BMI). MethodsaaThis cross-sectional study included 174 subjects with schizophrenia who were on 1) monotherapy with clozapine (CL), olanzapine (OL), or quetiapine (QT) (n=61), 2) monotherapy with risperidone (RSP) (n=89), or 3) monotherapy with aripiprizole (ARP), or ziprasidone (ZPS) (n=24) more than 1 year. Association between the prevalence of metabolic disturbances and groups were analysed using logistic regression after adjusting confounding variables including BMI. Analysese of covariance were used to compare the AAP groups in terms of the levels of metabolic parameters. ResultsaaThere were significant differences among groups in terms of the prevalence of hypertriglyceridemia (p=0.015), low HDL-cholesterol (p=0.017), and hyperglycemia (p=0.022) after adjusting for BMI. Triglyceride level (p=0.014) and the ratio of triglyceride to HDL-cholesterol (p=0.004) were significantly different among groups after adjusting for BMI. ConclusionaaIn conclusion, metabolic disturbances are significantly different in AAP groups even after adjusting BMI. AAPs may have direct effect on metabolic parameters. Blood lipid and glucose levels should be monitored regularly regardless of whether patients tend to gain weight.
Abstract
ObjectiveaaAtypical antipsychotic (AAP) treatment is associated with weight gain and metabolic disturbances such as dyslipidemia and dysglycemia. The metabolic disturbances are usually considered to develop secondary to weight gain. We performed the comparison of metabolic disturbances of three AAP group with different risk of metabolic side effect after adjusting for body mass to investigate whether any metabolic disturbances develop independently from body mass index (BMI). MethodsaaThis cross-sectional study included 174 subjects with schizophrenia who were on 1) monotherapy with clozapine (CL), olanzapine (OL), or quetiapine (QT) (n=61), 2) monotherapy with risperidone (RSP) (n=89), or 3) monotherapy with aripiprizole (ARP), or ziprasidone (ZPS) (n=24) more than 1 year. Association between the prevalence of metabolic disturbances and groups were analysed using logistic regression after adjusting confounding variables including BMI. Analysese of covariance were used to compare the AAP groups in terms of the levels of metabolic parameters. ResultsaaThere were significant differences among groups in terms of the prevalence of hypertriglyceridemia (p=0.015), low HDL-cholesterol (p=0.017), and hyperglycemia (p=0.022) after adjusting for BMI. Triglyceride level (p=0.014) and the ratio of triglyceride to HDL-cholesterol (p=0.004) were significantly different among groups after adjusting for BMI. ConclusionaaIn conclusion, metabolic disturbances are significantly different in AAP groups even after adjusting BMI. AAPs may have direct effect on metabolic parameters. Blood lipid and glucose levels should be monitored regularly regardless of whether patients tend to gain weight.
참고문헌 (36)
- Turner MS, "Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses", J Psychopharmacol, 20(6 suppl), pp.20~37 (2006)
- Nasrallah HA, "Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles", Mol Psychiatry, 13, pp.27~35 (2007)
- Newcomer JW, "Second-generation (atypical) antipsychotics and metabolic effects", CNS drugs, 19(Suppl 1), pp.1~93 (2005)
- Scigliano G, "Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis", CNS Drugs, 27, pp.249~257 (2013)
- Haupt DW, "Differential metabolic effects of antipsychotic treatments", Eur Neuropsychopharmcol, 16(Suppl 3), pp.S149~S155 (2006)
- Rummel-Kluge C, "Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons", Schizophrenia Bull, 38, pp.167~177 (2012)
- Meyer JM, "The effects of antipsychotic therapy on serum lipids: a comprehensive review", Schizophr Res, 70, pp.1~17 (2004)
- Henderson DC, "Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents : a frequently sampled intravenous glucose tolerance test and minimal model analysis", Arch Gen Psychiatry, 62, pp.19~28 (2005)
- Kang SH, "Cross-sectional prevalence of metabolic syndrome in Korean patients with schizophrenia", Schizophr Res, 128, pp.179~181 (2011)
- De Hert M, "Metabolic and cardiovascular adverse effects associated with antipsychotic drugs", Nat Rev Endocrinol, 8, pp.114~126 (2011)
- Meyer JM, "Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1", Schizophr Res, 101, pp.273~286 (2008)
- Grundy SM, "Diagnosis and management of the metabolic syndrome an American Heart Association", National Heart, Lung, and Blood Institute scientific statement, 2005, pp.112, 2735~2752
- World Health Organization, "The Asia-Pacific Perspective: Redefining Obesity and Its Treatment" (2000), World Health Organization
- Meyer JM, "A retrospective comparison of weight, lipid and glucose changes between risperidone and olanzapine-treated inpatients: Metabolic outcomes after 1 year", J Clin Psychiatry, 63, pp.1~2002 (2002)
- Atmaca M, "Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics", J Clin Psychiatry, 64, pp.598~604 (2003)
- Wirshing DA, "The effects of novel antipsychotics on glucose and lipid levels", J Clin Psychiatry, 63, pp.856~865 (2002)
- Henderson DC, "Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study", Am J Psychiatry, 157, pp.975~981 (2000)
- Subramanian S, "Hypertriglyceridemia secondary to obesity and diabetes", Biochim Biophys Acta, 1821, pp.819~825 (2012)
- Markham-Abedi C, "Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report", J Clin Psychiatry, 67, pp.1473~1474 (2006)
- Meyer JM, "Effects of atypical antipsychotics on weight and serum lipid levels", J Clin Psychiatry, 62(Suppl 27), pp.27~34 (2001)
- Nagamine T, "Olanzapine-induced elevation of serum triglyceride levels in a normal weight patient with schizophrenia", Internal Med, 47, pp.181~182 (2008)
- Reaven GM, "In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment", J Psychiatr Res, 43, pp.997~1002 (2009)
- Yan H, "Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia", Psychopharmacology (Berl), 229, pp.1~7 (2013)
- Canfrán-Duque A, "Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro", J Lipid Res, 54, pp.310~324 (2013)
- Newcomer JW, "Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia", Arch Gen Psychiatry, 59, pp.337~345 (2002)
- Melkersson KI, "Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses", J Clin Psychiatry, 61, pp.742~749 (2000)
- Teff KL, "Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease", Diabetes, 62, pp.3232~3240 (2013)
- Weiden PJ, "Obesity as a risk factor for antipsychotic noncompliance", Schizophr Res, 66, pp.51~57 (2004)
- Melkersson K, "Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism", Psychopharmacology (Berl), 175, pp.1~6 (2004)
- Tschoner A, "Metabolic side effects of antipsychotic medication", Int J Clin Pract, 61, pp.1356~1370 (2007)
- Mitchell A, "Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices", Psychol Med, 42, pp.125~147 (2012)
- Barnes TR, "A UK audit of screening for the metabolic side effects of antipsychotics in community patients", Schizophrenia Bull, 33, pp.1397~1403 (2007)
- Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies: development and validation", J Chronic Dis, 40, pp.373~383 (1987)
- Slagter SN, "Associations between smoking, components of metabolic syndrome and lipoprotein particle size", BMC Med, 11, pp.195~ (2013)
- Chengappa K, "Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review", Clin Ther, 24, pp.1576~1584 (2002)
- Correll CU, "Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials", J Am Acad Child Adolesc Psychiatry, 46, pp.687~700 (2007)